The Genomic and Epigenomic Landscapes of AML

Luca Mazzarella, Laura Riva, Lucilla Luzi, Chiara Ronchini, Pier Giuseppe Pelicci

Research output: Contribution to journalArticle

Abstract

A progressively better understanding of the genetic and epigenetic abnormalities underlying acute myeloid leukemia has changed clinical practice and affected the outcome of thousands of patients. Over the past decades, approaches focused on cloning, sequencing, and functional characterization of one or a few genes were the preferred (and the only possible) modality of investigation. The advent of disruptive new sequencing technologies brought about an unprecedented acceleration in our learning curve. Our view of the abnormalities required to generate and sustain leukemia is evolving from a piecemeal account based on individual lines of research into a comprehensive view of how all the important components (eg, transcriptional program, chromatin modifications, DNA sequence, alterations in noncoding genome) interact, in each patient and each leukemic cell. In this article, we provide an overall look at this complicated landscape and highlight outstanding issues for future research.

Original languageEnglish
Pages (from-to)259-272
Number of pages14
JournalSeminars in Hematology
Volume51
Issue number4
DOIs
Publication statusPublished - Oct 1 2014

Fingerprint

Epigenomics
Learning Curve
Acute Myeloid Leukemia
Chromatin
Organism Cloning
Leukemia
Genome
Technology
Research
Genes

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

The Genomic and Epigenomic Landscapes of AML. / Mazzarella, Luca; Riva, Laura; Luzi, Lucilla; Ronchini, Chiara; Pelicci, Pier Giuseppe.

In: Seminars in Hematology, Vol. 51, No. 4, 01.10.2014, p. 259-272.

Research output: Contribution to journalArticle

@article{b33fe971c3df4075914e6cf6fe8895e0,
title = "The Genomic and Epigenomic Landscapes of AML",
abstract = "A progressively better understanding of the genetic and epigenetic abnormalities underlying acute myeloid leukemia has changed clinical practice and affected the outcome of thousands of patients. Over the past decades, approaches focused on cloning, sequencing, and functional characterization of one or a few genes were the preferred (and the only possible) modality of investigation. The advent of disruptive new sequencing technologies brought about an unprecedented acceleration in our learning curve. Our view of the abnormalities required to generate and sustain leukemia is evolving from a piecemeal account based on individual lines of research into a comprehensive view of how all the important components (eg, transcriptional program, chromatin modifications, DNA sequence, alterations in noncoding genome) interact, in each patient and each leukemic cell. In this article, we provide an overall look at this complicated landscape and highlight outstanding issues for future research.",
author = "Luca Mazzarella and Laura Riva and Lucilla Luzi and Chiara Ronchini and Pelicci, {Pier Giuseppe}",
year = "2014",
month = "10",
day = "1",
doi = "10.1053/j.seminhematol.2014.08.007",
language = "English",
volume = "51",
pages = "259--272",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - The Genomic and Epigenomic Landscapes of AML

AU - Mazzarella, Luca

AU - Riva, Laura

AU - Luzi, Lucilla

AU - Ronchini, Chiara

AU - Pelicci, Pier Giuseppe

PY - 2014/10/1

Y1 - 2014/10/1

N2 - A progressively better understanding of the genetic and epigenetic abnormalities underlying acute myeloid leukemia has changed clinical practice and affected the outcome of thousands of patients. Over the past decades, approaches focused on cloning, sequencing, and functional characterization of one or a few genes were the preferred (and the only possible) modality of investigation. The advent of disruptive new sequencing technologies brought about an unprecedented acceleration in our learning curve. Our view of the abnormalities required to generate and sustain leukemia is evolving from a piecemeal account based on individual lines of research into a comprehensive view of how all the important components (eg, transcriptional program, chromatin modifications, DNA sequence, alterations in noncoding genome) interact, in each patient and each leukemic cell. In this article, we provide an overall look at this complicated landscape and highlight outstanding issues for future research.

AB - A progressively better understanding of the genetic and epigenetic abnormalities underlying acute myeloid leukemia has changed clinical practice and affected the outcome of thousands of patients. Over the past decades, approaches focused on cloning, sequencing, and functional characterization of one or a few genes were the preferred (and the only possible) modality of investigation. The advent of disruptive new sequencing technologies brought about an unprecedented acceleration in our learning curve. Our view of the abnormalities required to generate and sustain leukemia is evolving from a piecemeal account based on individual lines of research into a comprehensive view of how all the important components (eg, transcriptional program, chromatin modifications, DNA sequence, alterations in noncoding genome) interact, in each patient and each leukemic cell. In this article, we provide an overall look at this complicated landscape and highlight outstanding issues for future research.

UR - http://www.scopus.com/inward/record.url?scp=84907999624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907999624&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2014.08.007

DO - 10.1053/j.seminhematol.2014.08.007

M3 - Article

C2 - 25311739

AN - SCOPUS:84907999624

VL - 51

SP - 259

EP - 272

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 4

ER -